Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported financial results for the third quarter of fiscal year 2023, ending December 31, 2022. The company achieved consolidated revenues of $9.3 million, up 3% year-over-year, primarily driven by sales of generic Adderall products. Operating profits increased to $2.0 million, while net income rose to $2.96 million. For the nine-month period, revenues totaled $25.5 million, reflecting a 4% increase, but operating profits decreased to $4.1 million. A conference call is scheduled for February 15, 2023 to discuss these results and future updates.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) announced that it will release its third quarter financial results for the fiscal year 2023 on February 14, 2023. Management will host a live conference call on February 15, 2023, at 11:30 AM EST to discuss financial and operational outcomes, along with a general business update. Stockholders are encouraged to submit questions before the call. Elite Pharmaceuticals focuses on developing niche generic products and operates a cGMP and DEA registered facility for research and manufacturing in Northvale, NJ. For additional information, visit www.elitepharma.com.
Elite Pharmaceuticals (OTCQB:ELTP) announced positive results from pivotal fasted bioequivalence studies for a generic antimetabolite drug. IQVIA reported annual sales of $42 million for the generic market related to this product as of December 2022. These open-label studies demonstrated that the generic is bioequivalent to its branded counterpart, paving the way for Elite to compile data for an Abbreviated New Drug Application with the FDA.
Elite specializes in niche generic products and operates a registered facility in Northvale, NJ. For more details, visit www.elitepharma.com.
Elite Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) with the FDA for an undisclosed extended-release generic drug in the dopamine agonists class. This medication had US sales of about $12 million for the year ending August 31, 2022, according to IQVIA. The company develops niche generic products and operates a cGMP facility in Northvale, NJ. While the filing is a strategic move, it involves inherent risks and uncertainties that could impact future performance.
Elite Pharmaceuticals (OTCQB:ELTP) announced its financial results for the second quarter of fiscal year 2023, ending September 30, 2022, with consolidated revenues reaching $16.3 million, a 4% increase year-over-year. This growth is primarily due to revenues from generic Adderall. However, operating profits fell to $2.1 million, a decrease of $0.28 million compared to the previous year, while net income was reported at $1.82 million. A conference call is scheduled for November 15, 2022, to discuss results and updates.
Elite Pharmaceuticals (OTCQB:ELTP) announced that it will release its financial results for the second quarter of the 2023 fiscal year, ending September 30, 2022, on November 14, 2022. A live conference call is scheduled for November 15, 2022, at 11:30 AM EST, where management will discuss the financial and operational outcomes as well as provide a business update. Investors can submit questions via email prior to the call. Elite focuses on developing and manufacturing niche generic products, with a registered facility in Northvale, NJ.
Elite Pharmaceuticals reported positive results from pivotal bioequivalence studies for a generic extended-release drug in the dopamine agonist class. The studies confirmed that the generic product is bioequivalent to its branded counterpart. IQVIA reported an annual market revenue of $12 million for this product as of August 2022. Elite will file an Abbreviated New Drug Application with the FDA, supporting future growth potential. The company specializes in niche generic products and operates a cGMP and DEA registered facility in Northvale, NJ.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported its financial results for the first quarter of fiscal year 2023 ending June 30, 2022. Consolidated revenues increased by 9% to $7.7 million, driven by sales of generic Adderall products. Operating profits rose to $1.0 million, marking a $0.06 million increase from the prior year. Net income reached $0.31 million. A conference call is scheduled for August 16, 2022, to discuss these results and answer shareholder questions.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) reported significant financial results for the fiscal year ended March 31, 2022. Consolidated revenues grew by 27% to $32.3 million, largely driven by sales of generic Adderall and Naltrexone Tablets. Operating profits increased to $5.1 million, up $3.0 million year-over-year, while net income reached $8.9 million. The company is set to discuss these results in a conference call scheduled for June 30, 2022, at 11:30 AM EDT. For more details, stakeholders are encouraged to submit questions ahead of the call.
Elite Pharmaceuticals has received FDA approval for its generic version of Sabril (Vigabatrin USP) 500 mg powder for solution. This antiepileptic drug is indicated for refractory complex partial seizures, targeting patients with inadequate responses to alternative treatments. Lannett Company holds the exclusive marketing rights in the U.S. and territories, while Elite will manufacture and package the product. The collaboration entails shared profits from product net sales, enhancing Elite's market position in the specialty pharmaceutical sector.